Your browser doesn't support javascript.
loading
Melphalan-associated encephalopathy following autologous stem cell transplant: a transplanter's nightmare!
Shinde, Suchita; Guntiboina, Vinay Anand; Nag, Arijit; Podder, Dibakar; Chattopadhyay, Debranjani; Kumar, Jeevan; Bhave, Saurabh; Mishra, Deepak Kumar; Chandy, Mammen; Nair, Reena.
Afiliación
  • Shinde S; Department of Clinical Haematology and Cellular Therapies, Tata Medical Center, Kolkata, India.
  • Guntiboina VA; Department of Clinical Haematology and Cellular Therapies, Tata Medical Center, Kolkata, India.
  • Nag A; Department of Clinical Haematology and Cellular Therapies, Tata Medical Center, Kolkata, India.
  • Podder D; Department of Clinical Haematology and Cellular Therapies, Tata Medical Center, Kolkata, India.
  • Chattopadhyay D; Department of Clinical Haematology and Cellular Therapies, Tata Medical Center, Kolkata, India.
  • Kumar J; Department of Clinical Haematology and Cellular Therapies, Tata Medical Center, Kolkata, India.
  • Bhave S; Department of Clinical Haematology and Cellular Therapies, Tata Medical Center, Kolkata, India.
  • Mishra DK; Department of Laboratory Haematology, Tata Medical Center, Kolkata, India.
  • Chandy M; Department of Clinical Haematology and Cellular Therapies, Tata Medical Center, Kolkata, India.
  • Nair R; Department of Clinical Haematology and Cellular Therapies, Tata Medical Center, Kolkata, India.
Blood Cell Ther ; 7(2): 33-36, 2024 May 25.
Article en En | MEDLINE | ID: mdl-38854402
ABSTRACT
Melphalan-induced encephalopathy is a rare complication observed in patients undergoing autologous stem cell transplantation (ASCT) and is characterized by symptoms ranging from drowsiness to seizures. Previous reports have described similar cases, including a review of a large cohort of patients in whom melphalan-associated encephalopathy was identified in 2% of the patients undergoing ASCT. We describe the case of a 63-year-old male with Multiple Myeloma and underlying chronic kidney disease (CKD) who underwent ASCT with a reduced dose of melphalan due to renal dysfunction in complete remission following induction therapy and subsequent neurological deterioration, which necessitated an extensive evaluation of several neurological and infective etiologies. In this report, we highlight that melphalan-associated encephalopathy is a distinct entity complicating ASCT in patients with myeloma, especially in those with preexisting renal insufficiency, and consider its management.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Blood Cell Ther Año: 2024 Tipo del documento: Article País de afiliación: India Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Blood Cell Ther Año: 2024 Tipo del documento: Article País de afiliación: India Pais de publicación: Japón